Real-World Outcomes of Sevabertinib in HER2-Mutant Advanced NSCLC: A Bidirectional Cohort Study
Real-World Efficacy and Safety of Sevabertinib as Second-Line or Later-Line Therapy in Patients With HER2-Mutant Advanced Non-Small Cell Lung Cancer: An Observational, Bidirectional Cohort Study
This is a single-center, observational, bidirectional cohort study evaluating the real-world effectiveness, safety, and quality of life associated with sevabertinib in Chinese adults with HER2-mutant advanced non-small cell lung cancer receiving sevabertinib as second-line or later-line therapy. The study will include both retrospectively identified patients and prospectively enrolled patients. The primary objective is to evaluate real-world progression-free survival. Additional assessments include tumor response, overall survival, safety, and patient-reported quality of life.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Yi XIANG
- Telefonní číslo: +86-13816967846
- E-mail: xiangyiht@163.com
Studijní místa
-
-
Hainan
-
Qionghai, Hainan, Čína, 571400
- Nábor
- Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine (Hainan Boao Research Hospital)
-
Kontakt:
- Yi XIANG
- Telefonní číslo: +86-13816967846
- E-mail: xiangyiht@163.com
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Adult Chinese patients with unresectable locally advanced or metastatic non-squamous NSCLC harboring a documented HER2 (ERBB2) TKD activating mutation who receive sevabertinib as second-line or later-line therapy in routine clinical practice. The study includes both retrospectively identified patients and prospectively enrolled patients.
Popis
Inclusion Criteria:
- Age ≥18 years at the index date.
- Unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
- Documented HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutation.
- Received at least one prior systemic therapy for advanced NSCLC. Prior HER2-targeted antibody-drug conjugate (ADC) therapy is permitted, whereas prior HER2-targeted tyrosine kinase inhibitor (TKI) therapy is not permitted.
- For retrospectively included participants, sufficient baseline clinical, treatment, and prior follow-up data are available.
- Sevabertinib treatment has been determined by the treating physician based on clinical practice, or the participant has already initiated sevabertinib at screening.
Exclusion Criteria:
- History of Grade 3 or higher interstitial lung disease (ILD), or evidence of any clinically active ILD.
- Uncontrolled comorbid diseases or conditions, including but not limited to decompensated respiratory, cardiac, hepatic, or renal disease; ongoing or active infection, including active clinical tuberculosis; renal transplantation; or psychiatric/social conditions that may limit study compliance.
- Unstable brain metastases.
- Inability to comply with the study for any reason.
- Receipt of another unapproved investigational drug or non-drug treatment within 30 days before the index date or during the observation period.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: COHORT
- Časové perspektivy: OTHER
Počet skupin / kohort
Kohorty a intervence
Skupina / kohortaSkupina / kohorta |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Sevabertinib-Treated Cohort
Adult Chinese patients with HER2-mutant advanced non-small cell lung cancer receiving sevabertinib as second-line or later-line therapy in routine clinical practice. Treatment with sevabertinib is determined by the treating physician and is not assigned by the study protocol. |
Sevabertinib is administered as part of routine clinical care, generally at a dose of 20 mg orally twice daily with food until disease progression or unacceptable toxicity, according to the treating physician's clinical judgment. Treatment is not assigned by the study protocol. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Real-World Progression-Free Survival (rwPFS)
Časové okno: From the first dose of sevabertinib until the first documented disease progression or death from any cause, whichever occurs first, assessed up to 12 months.
|
rwPFS is defined as the time from the first dose of sevabertinib to the first documented disease progression or death from any cause, whichever occurs first. |
From the first dose of sevabertinib until the first documented disease progression or death from any cause, whichever occurs first, assessed up to 12 months.
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Investigator-Assessed Real-World Objective Response Rate (rwORR)
Časové okno: From the first dose of sevabertinib through the last available tumor response assessment, up to 12 months.
|
rwORR is defined as the proportion of evaluable participants whose best overall response is complete response (CR) or partial response (PR), as assessed by the investigator according to RECIST version 1.1. |
From the first dose of sevabertinib through the last available tumor response assessment, up to 12 months.
|
|
Investigator-Assessed Real-World Disease Control Rate (rwDCR)
Časové okno: From the first dose of sevabertinib through the last available tumor response assessment, up to 12 months.
|
rwDCR is defined as the proportion of evaluable participants who achieve CR, PR, or stable disease (SD). Confirmed and unconfirmed best overall responses will be analyzed separately. |
From the first dose of sevabertinib through the last available tumor response assessment, up to 12 months.
|
|
6-Month and 12-Month Progression-Free Survival Rates
Časové okno: At 6 months and 12 months after the first dose of sevabertinib.
|
The probabilities of participants being alive and free from disease progression at 6 months and 12 months after the first dose of sevabertinib. |
At 6 months and 12 months after the first dose of sevabertinib.
|
|
Incidence of Treatment-Related Adverse Events
Časové okno: From the first dose of sevabertinib through the last available safety assessment, up to 12 months.
|
The incidence of treatment-related adverse events of any grade and Grade 3 or higher will be assessed. Adverse events will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 6.0. |
From the first dose of sevabertinib through the last available safety assessment, up to 12 months.
|
|
Change From Baseline in EORTC QLQ-C30 Scores
Časové okno: Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
|
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) assesses cancer-related quality of life. Scores for each scale range from 0 to 100. Higher functional and global health status/quality-of-life scores indicate better functioning or quality of life, whereas higher symptom scores indicate worse symptoms. |
Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
|
|
Change From Baseline in NSCLC-SAQ Total Score
Časové okno: Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
|
The Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) assesses NSCLC-related symptoms. The total score ranges from 0 to 20, with higher scores indicating greater symptom severity. |
Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
|
|
Change From Baseline in EQ-5D-5L Index Score
Časové okno: Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
|
The EuroQol 5-Dimension 5-Level (EQ-5D-5L) assesses overall health status across five dimensions. Using the Chinese value set, index scores range from -0.391 to 1.000, with higher scores indicating better health status. |
Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
Další identifikační čísla studie
- RWS2026-003
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Individual participant data (IPD) are not planned to be shared with external researchers because the study uses sensitive clinical data derived from medical records and follow-up. Study data are de-identified and managed under applicable confidentiality, privacy, and institutional data security requirements, with access restricted to authorized study personnel.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .